VRTX
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.
Vertex Pharmaceuticals Incorporated (VRTX) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Growth (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-16 | C+ (2.6) | C- (1.9) | B+ (3.7) | B (3.4) | C+ (2.5) | C+ (2.8) |
| 2026-11-09 | C (2.5) | C- (1.9) | B+ (3.6) | B (3.4) | C+ (2.5) | C+ (2.8) |
| 2026-11-04 | C+ (2.6) | C- (2.1) | B+ (3.7) | B+ (3.6) | C+ (2.6) | B- (2.9) |
| 2026-11-03 | C+ (2.6) | C- (2.1) | B+ (3.7) | B (3.4) | C (2.5) | B- (2.9) |
| 2026-11-02 | C+ (2.6) | C- (2.1) | B+ (3.7) | B (3.4) | C (2.2) | C+ (2.8) |